Assay and drug development technologies最新文献_第3页

Drug Repurposing Patent Applications January-March 2024. 2024 年 1-3 月的药物再利用专利申请。

IF 1.8 4区医学

Assay and drug development technologies Pub Date : 2024-06-11 DOI: 10.1089/adt.2024.047

Hermann A M Mucke

引用次数: 0

Beyond the Maze: Recent Advancements in Molecular and Cellular Tethered Drug Delivery Systems. 超越迷宫：分子和细胞系留给药系统的最新进展。

IF 1.6 4区医学

Assay and drug development technologies Pub Date : 2024-05-01 Epub Date: 2024-05-08 DOI: 10.1089/adt.2024.025

Dilpreet Singh

{"title":"Beyond the Maze: Recent Advancements in Molecular and Cellular Tethered Drug Delivery Systems.","authors":"Dilpreet Singh","doi":"10.1089/adt.2024.025","DOIUrl":"10.1089/adt.2024.025","url":null,"abstract":"\u0000 The relentless pursuit of precision medicine has catalyzed the development of molecular and cellular tethered drug delivery systems, a burgeoning field that stands to redefine the paradigms of therapeutic delivery. This review encapsulates the cutting-edge advancements within this domain, emphasizing the engineering of molecular tethers and cellular vectors designed to ferry therapeutics directly to their target sites with unparalleled specificity and efficiency. By exploiting the unique biochemical signatures of disease states, these systems promise a substantial reduction in off-target effects and an enhancement in drug bioavailability, thereby mitigating the systemic side effects that are often associated with conventional drug therapies. Through a synthesis of recent research findings, this review highlights the innovative approaches being explored in the design and application of these tethered systems, ranging from nanotechnology-based solutions to genetically engineered cellular carriers. The potential of these systems to provide targeted therapy for a wide array of diseases, including cancer, autoimmune disorders, and neurological conditions, is thoroughly examined. This abstract aims to provide a succinct overview of the current state and future prospects of molecular and cellular tethered drug delivery systems in advancing the frontiers of precision medicine.\u0000 ","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"203-215"},"PeriodicalIF":1.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140875718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antidiabetic Evaluation of Kigelia pinnata Root Bark Extract in Streptozotocin-Induced Type-2 Diabetes Model of Rats. 松萝根皮提取物在链脲佐菌素诱导的 2 型糖尿病模型大鼠中的抗糖尿病评价

IF 1.8 4区医学

Assay and drug development technologies Pub Date : 2024-05-01 Epub Date: 2024-03-28 DOI: 10.1089/adt.2023.104

Ravindra Kumar, Neeraj Kumar, Satyendra Kumar Rajput, Sudhanshu Mallan, Arun Kumar, Balwant Singh Rawat, Naresh Kumar Rangra, Shamsher Singh

{"title":"Antidiabetic Evaluation of Kigelia pinnata Root Bark Extract in Streptozotocin-Induced Type-2 Diabetes Model of Rats.","authors":"Ravindra Kumar, Neeraj Kumar, Satyendra Kumar Rajput, Sudhanshu Mallan, Arun Kumar, Balwant Singh Rawat, Naresh Kumar Rangra, Shamsher Singh","doi":"10.1089/adt.2023.104","DOIUrl":"10.1089/adt.2023.104","url":null,"abstract":"Diabetes mellitus (DM) is the most common endocrine disorder characterized by increased blood glucose levels resulting from defective insulin secretion, resistance to insulin action, or both. DM is often associated with severe complications, and there is an increasing appreciation that cognitive function declines in DM. The aim of this research work was to evaluate Kigelia pinnata root bark extract in Streptozotocin (STZ)-induced type-2 diabetes. Experimental diabetes was induced by a single administration of STZ (60 mg/kg, intraperitoneal [i.p.]), immediately after the STZ administration, and all animals were fed with normal food and water. Nicotinamide was administered (120 mg/kg, i.p.) 15 min before STZ. The development of hyperglycemia was confirmed by the elevated blood glucose levels determined at fixed intervals, which was confirmed by measuring fasting blood glucose levels in rats' blood taken from the tail vein. Supplementation with ethanolic extract of K. pinnata root bark (EEKP) significantly reduced the elevated blood glucose in STZ-induced hyperglycemia in rats. EEKP significantly restored the biochemical and antioxidant defense system. On the final day of the protocol, the extract also reduced inflammatory cytokines in the blood serum.","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"169-180"},"PeriodicalIF":1.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140304553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exosomes: Key Players for Treatment of Cancer and Their Future Perspectives. 外泌体：癌症治疗的关键角色及其未来前景。

IF 1.6 4区医学

Assay and drug development technologies Pub Date : 2024-04-01 Epub Date: 2024-02-26 DOI: 10.1089/adt.2023.026

Reena Gupta, Jitendra Gupta, Suchismita Roy

引用次数: 0

High-Throughput Methods for the Discovery of Small Molecule Modulators of Pancreatic Beta-Cell Function and Regeneration. 发现胰腺 Beta 细胞功能和再生小分子调节剂的高通量方法。

IF 1.6 4区医学

Assay and drug development technologies Pub Date : 2024-04-01 Epub Date: 2024-03-25 DOI: 10.1089/adt.2023.119

Sean M McCarty, Martin C Clasby, Jonathan Z Sexton

{"title":"High-Throughput Methods for the Discovery of Small Molecule Modulators of Pancreatic Beta-Cell Function and Regeneration.","authors":"Sean M McCarty, Martin C Clasby, Jonathan Z Sexton","doi":"10.1089/adt.2023.119","DOIUrl":"10.1089/adt.2023.119","url":null,"abstract":"\u0000 The progression of type II diabetes (T2D) is characterized by a complex and highly variable loss of beta-cell mass, resulting in impaired insulin secretion. Many T2D drug discovery efforts aimed at discovering molecules that can protect or restore beta-cell mass and function have been developed using limited beta-cell lines and primary rodent/human pancreatic islets. Various high-throughput screening methods have been used in the context of drug discovery, including luciferase-based reporter assays, glucose-stimulated insulin secretion, and high-content screening. In this context, a cornerstone of small molecule discovery has been the use of immortalized rodent beta-cell lines. Although insightful, this usage has led to a more comprehensive understanding of rodent beta-cell proliferation pathways rather than their human counterparts. Advantages gained in enhanced physiological relevance are offered by three-dimensional (3D) primary islets and pseudoislets in contrast to monolayer cultures, but these approaches have been limited to use in low-throughput experiments. Emerging methods, such as high-throughput 3D islet imaging coupled with machine learning, aim to increase the feasibility of integrating 3D microtissue structures into high-throughput screening. This review explores the current methods used in high-throughput screening for small molecule modulators of beta-cell mass and function, a potentially pivotal strategy for diabetes drug discovery.\u0000 ","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"148-159"},"PeriodicalIF":1.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug Repurposing Patent Applications October-December 2023. 2023 年 10 月至 12 月的药物再利用专利申请。

IF 1.8 4区医学

Assay and drug development technologies Pub Date : 2024-04-01 Epub Date: 2024-03-05 DOI: 10.1089/adt.2024.011

Hermann A M Mucke

引用次数: 0

A Perspective on Various Facets of Nanoemulsions and its Commercial Utilities. 透视纳米乳剂的方方面面及其商业用途。

IF 1.8 4区医学

Assay and drug development technologies Pub Date : 2024-04-01 Epub Date: 2024-03-14 DOI: 10.1089/adt.2023.042

Isha Mishra, Raghav Mishra, Ashutosh Dubey, Prashant Kumar Dhakad

{"title":"A Perspective on Various Facets of Nanoemulsions and its Commercial Utilities.","authors":"Isha Mishra, Raghav Mishra, Ashutosh Dubey, Prashant Kumar Dhakad","doi":"10.1089/adt.2023.042","DOIUrl":"10.1089/adt.2023.042","url":null,"abstract":"\u0000 Nanotechnology is a captivating contemporary technology owing to its extensive range of potential applications. This study emphasizes nanomaterials, substances with a size <100 nm, offering better qualities than coarse particles. Nanoparticles have several advantages compared with conventional drug delivery methods, including enhanced bioavailability and a larger surface area because of their smaller particle size. These characteristics make the nanoparticles a viable clinical candidate. Controlled-release drug delivery systems and targeted drug delivery systems rely heavily on nanoparticles. Because traditional drug delivery methods fail to achieve targeted drug delivery, resulting in toxicity, low bioavailability, poor therapeutic outcomes, and so on, these drug nanoparticles excel in all these areas. Researchers are already interested in developing drug delivery systems such as niosomes, bilosomes, and dendrimers. Nanoemulsion is one of these technologies; nanoemulsions outperform traditional emulsions in terms of pharmacodynamics and pharmacokinetics. Nanoemulsion effectively surpasses the constraints of standard emulsions, primarily by offering enhanced bioavailability, reduced toxicity, improved absorption, and the potential to be used in targeted drug delivery or controlled-release drug delivery systems. This particular work explores several aspects of nanoemulsions, including their constituents, classification, techniques for preparation, criteria for assessment, commercial applications, and future prospects.\u0000 ","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"97-117"},"PeriodicalIF":1.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140136418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimization of Lurasidone HCl-Loaded PLGA Nanoparticles for Intramuscular Delivery: Enhanced Bioavailability, Reduced Dosing Frequency, Pharmacokinetics, and Therapeutic Outcomes. 优化用于肌内给药的 Lurasidone HCl-Loaded PLGA 纳米颗粒：提高生物利用度、减少给药次数、药代动力学和治疗效果。

IF 1.8 4区医学

Assay and drug development technologies Pub Date : 2024-02-01 Epub Date: 2023-12-27 DOI: 10.1089/adt.2023.089

Nikita Macwan, Hemil S Patel, Rakesh K Sharma, Nihali Jain, Hemal Tandel

{"title":"Optimization of Lurasidone HCl-Loaded PLGA Nanoparticles for Intramuscular Delivery: Enhanced Bioavailability, Reduced Dosing Frequency, Pharmacokinetics, and Therapeutic Outcomes.","authors":"Nikita Macwan, Hemil S Patel, Rakesh K Sharma, Nihali Jain, Hemal Tandel","doi":"10.1089/adt.2023.089","DOIUrl":"10.1089/adt.2023.089","url":null,"abstract":"This study aimed to develop a nanoparticle drug delivery system using poly (lactic-co-glycolic acid) (PLGA) for enhancing the therapeutic efficacy of lurasidone hydrochloride (LH) in treatment of schizophrenia through intramuscular injection. LH-loaded PLGA nanoparticles (LH-PNPs) were prepared using the nanoprecipitation technique and their physicochemical characteristics were assessed. Particle size (PS), zeta potential, morphology, % encapsulation efficiency, % drug loading, drug content, and solid-state properties were analyzed. Stability, in vitro release, and in vivo pharmacokinetic studies were conducted to evaluate the therapeutic efficacy of the developed LH-PNPs. The optimized batch of LH-PNPs exhibited a narrow and uniform PS distribution before and after lyophilization, with sizes of 112.7 ± 1.8 nm and 115.0 ± 1.3 nm, respectively, and a low polydispersity index. The PNPs showed high drug entrapment efficiency, drug loading, and drug content uniformity. Solid-state characterization indicated good stability and compatibility, with a nonamorphous state. The drug release profile demonstrated sustained release behavior. Intramuscular administration of LH-PNPs in rats resulted in a significantly prolonged mean residence time compared with the drug suspension. These findings highlight that intramuscular delivery of the LH-PNP formulation is a promising approach for enhancing the therapeutic efficacy of LH in treatment of schizophrenia.","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"53-62"},"PeriodicalIF":1.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139048280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential of Nanocarrier-Associated Approaches for Better Therapeutic Intervention in the Management of Glioblastoma. 纳米载体相关方法在胶质母细胞瘤治疗中更好的治疗干预潜力。

IF 1.8 4区医学

Assay and drug development technologies Pub Date : 2024-02-01 Epub Date: 2024-01-09 DOI: 10.1089/adt.2023.073

Vikram, Shobhit Kumar, Javed Ali, Sanjula Baboota

{"title":"Potential of Nanocarrier-Associated Approaches for Better Therapeutic Intervention in the Management of Glioblastoma.","authors":"Vikram, Shobhit Kumar, Javed Ali, Sanjula Baboota","doi":"10.1089/adt.2023.073","DOIUrl":"10.1089/adt.2023.073","url":null,"abstract":"\u0000 Glioblastoma, commonly known as glioblastoma multiforme (GBM), is one of the deadliest and most invasive types of brain cancer. Two factors account for the majority of the treatment limitations for GBM. First, the presence of the blood-brain barrier (BBB) renders malignancy treatment ineffective, leading to recurrence without full recovery. Second, several adverse effects are associated with the drugs used in conventional GBM treatment. Recent studies have developed nanocarrier systems, such as liposomes, polymeric micelles, dendrimers, nanosuspensions, nanoemulsions, nanostructured lipid carriers, solid lipid nanocarriers, metal particles, and silica nanoparticles, which allow drug-loaded formulations to penetrate the BBB more effectively. This has opened up new possibilities for overcoming therapy issues. Extensive and methodical searches of databases such as PubMed, Science Direct, Google Scholar, and others were conducted to gather relevant literature for this work, using precise keyword combinations such as \"GBM,\" \"brain tumor,\" and \"nanocarriers.\" This review provides deep insights into the administration of drugs using nanocarriers for the management of GBM and explores new advancements in nanotechnology. It also highlights how scientific developments can be explained in connection with hopeful findings about the potential of nanocarriers for the future successful management of GBM.\u0000 ","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"73-85"},"PeriodicalIF":1.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139401569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and Validation of Reverse-Phase High-Performance Liquid Chromatography Method for Simultaneous Estimation of Doxorubicin and Clotrimazole. 用于同时测定多柔比星和克霉唑的反相高效液相色谱法的开发与验证

IF 1.8 4区医学

Assay and drug development technologies Pub Date : 2024-02-01 Epub Date: 2023-12-27 DOI: 10.1089/adt.2023.057

Priyanka Sharma, Bhupinder Kapoor, Md Sadique Hussain, Gurvinder Singh, Pooja Rani, Balraj Saini, Pankaj Wadhwa, Rajesh Kumar

{"title":"Development and Validation of Reverse-Phase High-Performance Liquid Chromatography Method for Simultaneous Estimation of Doxorubicin and Clotrimazole.","authors":"Priyanka Sharma, Bhupinder Kapoor, Md Sadique Hussain, Gurvinder Singh, Pooja Rani, Balraj Saini, Pankaj Wadhwa, Rajesh Kumar","doi":"10.1089/adt.2023.057","DOIUrl":"10.1089/adt.2023.057","url":null,"abstract":"A reverse-phase high-performance liquid chromatographic (RP-HPLC) method was developed to analyze the simultaneous estimation of doxorubicin and clotrimazole. The method was achieved by Nucleodur C18 column with dimension 250 × 4.6 mm (5 μm) using gradient elution. The mobile phase contained 0.2% formic acid (pH 3.2) and acetonitrile. The flow rate was kept at 1.0 mL/min and detection and quantitation of both drugs (doxorubicin and clotrimazole) were achieved using a photodiode array detector at 276 nm, which was the isosbestic point for both drugs. The proposed method was validated according to the current International Council for Harmonization of Technical Requirements of Pharmaceuticals for Human Use guidelines for specificity, linearity, accuracy, precision, and robustness. The developed method showed a linear response (R2 > 0.999), and was accurate (recoveries 97%-103%), precise (resolution ≤1.0%), sensitive, and specific. Thus, the developed RP-HPLC method for the simultaneous estimation of both drugs was successfully validated and can be utilized for the estimation of these drugs in the formulations being developed.","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"86-96"},"PeriodicalIF":1.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139048279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0